“The transient agronomic technology we pioneered holds a very high promise, particularly because of speed and low cost of its deployment”, said Prof. Yuri Gleba, NOMAD’s CEO. “We expect that the technology will gain regulatory approval and commercial recognition initially in certain niche areas, before garnering attention for mainstream application on large-acreage major crops. One such application area is the production of commercial seed, where production can be made simpler and more efficient through acceleration of flowering time or transient control of male sterility. The other would be a more rapid deployment of orphan crops (millet, amaranth, buckwheat, cowpea, marihuana, etc.) for flowering control, drought tolerance, product quality improvement and such. Current swift approval and adoption of RNA-based viral vaccines for human health tells us that, because of its inherent speed and efficacy, the acceptance of RNA transfection-based agriculture, too, is likely to be accelerated during forthcoming and unavoidable major plant pathogen outbreaks.”
NOMAD Bioscience GmbH is a plant biotechnology company developing a broad range of biotechnology products manufactured in plants. Among the product candidates in development are antiviral biologics, non-antibiotic antimicrobials (bacterial bacteriocins and phage endolysins) for food safety and medicine markets, as well as natural proteins thaumatins as taste modifiers or high intensity non-caloric sweeteners. Corporate offices are headquartered in Munich, Germany and the Company’s Research Division is located in Halle, Germany. NOMAD Bioscience GmbH has also a wholly owned subsidiary UAB Nomads (Vilnius, Lithuania).
Nomad Bioscience GmbH
Weinbergweg 22
06120 München
Telefon: +49 (345) 1314-2600
http://www.nomadbioscience.com